Incomplete informed consent for psychotropic medications
Summary
The facility failed to obtain and maintain complete informed consent for psychotropic medications before administration for multiple residents. The report identified deficiencies involving Resident 1, Resident 2, Resident 13, Resident 16, and Resident 106, all of whom were receiving psychotropic medications such as antipsychotics, antidepressants, and anti-anxiety medications. Facility policies required staff and the physician to review the indication, rationale, alternatives, risks and benefits, and the resident’s or representative’s right to accept or decline treatment before documented consent was obtained, and to verify informed consent before administration. For Resident 1, the record showed diagnoses including dementia, depression, and anxiety disorder, and the resident was documented as having severe cognitive impairment and no capacity to understand and make decisions. The MAR showed administration of divalproex sodium, trazodone HCL, and Ativan from 2/1/2026 through 2/10/2026. The chart did not contain informed consent for divalproex or trazodone, and the Ativan consent form was incomplete because it did not include the resident’s diagnosis, duration of use, or specific observable behaviors indicating the purpose of the medication. Staff interviews confirmed that consent for trazodone and divalproex was missing and that the Ativan consent was incomplete. For Resident 2, the record showed dementia, aphasia, dependence on a respirator, inability to speak, and severe cognitive impairment, with Family Member 4 identified as the responsible party. The psychotropic consent form for quetiapine indicated verbal consent from the resident, but it did not include a date and did not show consent from the responsible party or representative. Staff stated the resident could not verbally consent and that the responsible party should have provided consent. For Resident 16, the record showed bipolar disorder, major depressive disorder, and schizophrenia, with fluctuating capacity to understand and make decisions. The psychotropic medication disclosures for Seroquel and escitalopram lacked the resident or representative signature and lacked physician counter-signatures, and disclosures for trazodone and buspirone also lacked physician signatures. For Resident 13, the record showed bipolar disorder, depression, and anxiety, and the disclosures for risperidone, trazodone, and buspirone were missing required physician information and signatures. For Resident 106, the record showed major depressive disorder and Alzheimer’s disease, with severe cognitive impairment and no capacity to make decisions. The consent form for imipramine was left unsigned by the resident’s representative and did not include the resident’s diagnosis or specific behaviors, and staff stated there was no valid consent for the medication.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.